References
- Rang H, Dale MM, Ritter JM, Moore PK. Pharmacology. Churchill Livingstone, Edinburg, 2003.
- Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med 2005;353:1711–1723.
- Murphy K, Travers, P, Walport M. Janeway’s immunobiology. Gardland Science, Newyork, 2007.
- Karsh J. Anti-inflammatory drugs: what is safe? Can Med Assoc J. 2006,175 449.
- Wu S., Ng LT, Lin DL, et al. Physalis peruviana extract induces apoptosis in human Hep G2 cells through CD95/CD95L system and the mitochondrial signaling transduction pathway. Cancer Lett 2004;215:199–208.
- Wu SJ, Ng LT, Huang YM, et al. Antioxidant activities of Physalis peruviana. Biological PharmaceutBull 2005;28:963–966.
- Wu SJ, Tsai, JY, Chang SP, et al. Supercritical carbon dioxide extract exhibits enhanced antioxidant and anti-inflammatory activities of Physalis peruviana. J Ethnopharmacol 2006;108:407–413.
- Franco LA, Matiz GE, Calle J, et al. Antiinflammatory activity of extracts and fractions obtained from Physalis peruviana L. calyces. Biomedica 2007;27:110–115.
- de Fries R, Mitsuhashi M. Quantification of mitogen induced human lymphocyte proliferation: comparison of alamarBlue assay to 3H-thymidine incorporation assay. J Clin Lab Anal 1995;9 (2):89–95.
- Osorio E, Arango GJ, Jimenez N, et al. Antiprotozoal and cytotoxic activities in vitro of Colombian Annonaceae. J Ethnopharmacol 2007;111(3):630–635.
- Raynaud-Le Grandic S, Fourneau C, Laurens A, et al. In vitro antileishmanial activity of acetogenins from Annonaceae. Biomed Pharmacother2004;58(6–7):388–392.
- Saravia NG, Nicholls RS Leishmaniasis: a public health challenge that demands concerted effort and will (editorial). Biomedica 2006;26(Suppl 1):7–9.
- Jones DE, Elloso MM, Scott P. Host susceptibility factors to cutaneous leishmaniasis. Front Biosci 1998;3:1171–1180.
- Aguilar-Torrentera F, Carlier, Y. Immunological factors governing resistance and susceptibility of mice to Leishmania major infection. Rev. Latinoam. Microbiol 2001;43:35–142.
- Teixeira MJ, Teixeira CR, Andrade BB, et al. Chemokines in host-parasite interactions in leishmaniasis. Trends Parasitol 2006;22:32–40.
- Bretscher PA, Ogunremi O, Menon J.N Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states. Behring Inst Mitt 1997; (98):153–159.
- Crisby, M. Modulation of the inflammatory process by statins. Drug Today (Barc) 2003;39:137–143.
- Allison AC, Cacabelos R, Lombardi VR, et al. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 2001;25(7):1341–1357.
- Bultzingslowen I, Jontell M. Macrophages, dendritic cells and T lymphocytes in rat buccal mucosa and dental pulp following 5-fluorouracil treatment. Eur J Oral Sci 1999;107(3):194–201.
- Vasquez RE, Soong L. CXCL10/gamma interferon-inducible protein 10-mediated protection against Leishmania amazonensis infection in mice. Infect Immun 2006;74(12):6769–6777.
- Dey. , Majumder N, Bhattacharyya Majumdar S, et al. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice. Scand J Immunol 2007;66(6):671–683.
- Brandonisio O, Panaro MA, Fumarola I., et al. Macrophage chemotactic protein-1 and macrophage inflammatory protein-1 alpha induce nitric oxide release and enhance parasite killing in Leishmania infantum-infected human macrophages. Clin Exp Med 2002;2 (3):125–129.
- Schulte A, Ruehl-Fehlert C. Regulatory aspects of immunotoxicology. Exp Toxicol Pathol 2006;57(5–6):385–389.
- Spanhaak S. The ICH S8 immunotoxicity guidance. Immune function assessment and toxicological pathology: autonomous or synergistic methods to predict immunotoxicity? Exp Toxicol Pathol 2006;57:373–376.